By Hilary Rosselot
Asuragen Presents During the 2022 Industry Updates Keynote at the 18th International Fragile X Conference
Stela Filipovic-Sadic, a manager of Research & Development at Asuragen, presented Asuragen’s molecular testing capabilities for FMR1 and Fragile X, and showed how new technologies drive progress in the field. Asuragen has been a part of the Fragile X community for years. Their tests have been used to help patients, clinicians, and researchers aid in diagnosis, screen potential carriers, stratify risk of Fragile X being passed onto the next generation, and connect patients to new therapies.
Learn more about Asuragen by watching their 2022 Industry Updates presentation or visiting their website.
Check out the Behind the Mystery of Fragile X Syndrome segment sponsored by Asuragen.
about
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
Published: Newborn, Carrier, and Early Childhood Screening Recommendations for Fragile X
The NFXF is pleased to see the recent publication of Newborn, Carrier, and Early Childhood Screening Recommendations for Fragile X in Pediatrics, the official Journal of the American Academy of Pediatrics.
Dr. Craig Erickson Discusses the Drug Acamprosate for the Treatment of FXS
Acamprosate, a drug used to treat alcohol abuse, improves communication and social behaviors associated with a common form of autism. IU autism researcher Craig Erickson, MD, will discuss his ongoing study of acamprosate and Fragile [...]